Good news on the vaccine front has had an immediate and tantalizing effect on the travel sector, suggesting many passengers are raring to get going again.
On Tuesday, the U.K.-based low-cost airline EasyJet issued results that were mostly gloomy—it posted its first annual loss, of $1.68 billion, in its quarter-century history. But it also pointed to a glimmer of hope.
When Pfizer and BioNTech announced their promising COVID-19 vaccine trial results last week Monday, said EasyJet CEO Johan Lundgren, the carrier’s bookings surged by 50%. According to Reuters, he added that the momentum continued this week Monday, when Moderna also announced a very high efficacy for its candidate vaccine.
